PF-06651600 + Placebo

Phase 2Terminated

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alopecia Areata

Conditions

Alopecia Areata

Trial Timeline

Sep 15, 2020 → May 7, 2024

NCT ID

NCT04517864

About PF-06651600 + Placebo

PF-06651600 + Placebo is a phase 2 stage product being developed by Pfizer for Alopecia Areata. The current trial status is terminated. This product is registered under clinical trial identifier NCT04517864. Target conditions include Alopecia Areata.

What happened to similar drugs?

1 of 20 similar drugs in Alopecia Areata were approved

Approved (1) Terminated (0) Active (19)

🔄CTP-543Sun PharmaceuticalPhase 3

🔄Deuruxolitinib + PlaceboSun PharmaceuticalPhase 3

✅Baricitinib 4 MG Oral TabletEli LillyApproved

🔄Baricitinib + PlaceboEli LillyPhase 3

🔄minoxidilJohnson & JohnsonPhase 3

🔄5% Minoxidil + 2% MinoxidilJohnson & JohnsonPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04517864	Phase 2	Terminated	Sep 15, 2020	May 7, 2024	Alopecia Areata
NCT03232905	Phase 1	Completed	Aug 30, 2017	Nov 22, 2017	Healthy

Competing Products

20 competing products in Alopecia Areata

See all competitors

Product	Company	Stage	Hype Score
Baricitinib	Eli Lilly	Phase 2	42
CTP-543	Sun Pharmaceutical	Phase 2/3	42
CTP-543	Sun Pharmaceutical	Phase 3	40
Deuruxolitinib + Placebo	Sun Pharmaceutical	Phase 3	47
Baricitinib + Placebo	Eli Lilly	Phase 2/3	38
Baricitinib 4 MG Oral Tablet	Eli Lilly	Approved	47
Baricitinib + Placebo	Eli Lilly	Phase 3	47
Baricitinib + Placebo	Eli Lilly	Phase 3	40
minoxidil	Johnson & Johnson	Phase 3	40
5% Minoxidil + 2% Minoxidil	Johnson & Johnson	Phase 3	40
Minoxidil + vehicle of 5% Minoxidil topical foam	Johnson & Johnson	Phase 2	35
5% Minoxidil Topical Foam + Vehicle Topical Foam	Johnson & Johnson	Phase 3	40
Upadacitinib + Upadacitinib Placebo	AbbVie	Phase 3	47
Upadacitinib + Placebo	AbbVie	Phase 3	47
Secukinumab + Placebo	Novartis	Phase 2	27
Daxdilimab	Amgen	Phase 2	35
Ritlecitinib	Pfizer	Pre-clinical	30
LITFULO	Pfizer	Pre-clinical	30
Ritlecitinib	Pfizer	Pre-clinical	33
Ritlecitinib higher dose + Ritlecitinib lower dose + Placebo	Pfizer	Phase 3	47